Atopic Dermatitis Emerging Therapies Rocatinlimab (KHK4083/AMG-451): Amgen/Kyowa Kirin Rocatinlimab (KHK4083/AMG 451) is an anti-OX40 human monoclonal antibody that inhibits and reduces the number ...

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the pipeline.

Pipeline candidates in development include Amgen and Kyowa Kirin’s rocatinlimab, Sanofi’s amlitelimab, and Astria Therapeutics’ telazrolimab. Another class with a potential future in AD is ...

Beyond MariTide, Amgen's pipeline depth is impressive. Rocatinlimab for atopic dermatitis has delivered stellar Phase 3 results across multiple studies, with the Ignite trial showing 42.3% of ...

Amgen (NASDAQ: AMGN) is doing something unusual in 2025. The biotech giant's shares are up 7.2% for the year as I write this ...